SST and neoplasm: In addition, TT-232 had practically no growth hormone release inhibitory activity either in superfused rat pituitary cells or in rats in vivo (Kéri et al, 1993a, 1993b, 1996), while the application of various other somatostatin analogues (Robbins, 1996; Schally, 1988; Janecka et al, 2001) in tumour therapy is limited because of their endocrine side effects (Setyono-Han et al, 1987).